Genomma Lab Internacional SAB de CV Announces Earnings Results for the First Quarter Ended March 31, 2020
April 22, 2020 at 06:07 pm EDT
Share
Genomma Lab Internacional SAB de CV announced earnings results for the first quarter ended March 31, 2020. For the quarter, the company announced net sales of MXN 3,334.5 million compared to MXN 3,137.9 million a year ago. Operating income was MXN 640.6 million compared to MXN 597.1 million a year ago. Net income was MXN 373.6 million compared to MXN 252.3 million a year ago.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
